Moderna (NASDAQ:MRNA) PT Lowered to $139.00 at The Goldman Sachs Group

Moderna (NASDAQ:MRNA) had its price target trimmed by The Goldman Sachs Group from $178.00 to $139.00 in a research report report published on Monday, Benzinga reports. The firm currently has a buy rating on the stock.

Several other equities research analysts also recently commented on MRNA. TD Cowen lowered their target price on shares of Moderna from $70.00 to $60.00 and set a hold rating for the company in a research note on Friday, September 13th. Piper Sandler lowered their target price on shares of Moderna from $157.00 to $115.00 and set an overweight rating for the company in a research note on Friday, September 13th. William Blair reaffirmed a market perform rating on shares of Moderna in a research note on Thursday, June 27th. Oppenheimer downgraded shares of Moderna from an outperform rating to a market perform rating in a research note on Friday, September 13th. Finally, Bank of America lowered their target price on shares of Moderna from $130.00 to $110.00 and set a neutral rating for the company in a research note on Friday, September 13th. Two analysts have rated the stock with a sell rating, thirteen have given a hold rating and four have given a buy rating to the stock. According to MarketBeat, the company currently has an average rating of Hold and an average price target of $100.44.

Moderna Trading Down 3.0 %

Shares of NASDAQ MRNA opened at $69.86 on Monday. The company’s 50 day simple moving average is $92.28 and its 200 day simple moving average is $111.27. Moderna has a fifty-two week low of $62.55 and a fifty-two week high of $170.47. The firm has a market capitalization of $26.77 billion, a P/E ratio of -4.46 and a beta of 1.68. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.09 and a quick ratio of 3.92.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings data on Thursday, August 1st. The company reported ($3.33) earnings per share for the quarter, beating the consensus estimate of ($3.47) by $0.14. Moderna had a negative net margin of 116.18% and a negative return on equity of 21.35%. The business had revenue of $241.00 million for the quarter, compared to analyst estimates of $128.41 million. During the same period in the prior year, the business posted ($3.62) earnings per share. Moderna’s revenue was down 29.9% compared to the same quarter last year. On average, analysts predict that Moderna will post -9.52 EPS for the current year.

Insider Buying and Selling at Moderna

In other Moderna news, CFO James M. Mock sold 689 shares of the stock in a transaction on Monday, July 8th. The shares were sold at an average price of $118.24, for a total value of $81,467.36. Following the completion of the sale, the chief financial officer now owns 7,269 shares in the company, valued at $859,486.56. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other news, Director Noubar Afeyan sold 15,000 shares of the firm’s stock in a transaction dated Wednesday, June 26th. The shares were sold at an average price of $127.22, for a total transaction of $1,908,300.00. Following the completion of the sale, the director now owns 2,284,015 shares in the company, valued at approximately $290,572,388.30. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO James M. Mock sold 689 shares of the firm’s stock in a transaction dated Monday, July 8th. The stock was sold at an average price of $118.24, for a total transaction of $81,467.36. Following the sale, the chief financial officer now owns 7,269 shares of the company’s stock, valued at approximately $859,486.56. The disclosure for this sale can be found here. Insiders sold a total of 93,158 shares of company stock worth $11,167,312 over the last quarter. 15.70% of the stock is currently owned by insiders.

Institutional Trading of Moderna

A number of hedge funds have recently modified their holdings of the stock. Sanctuary Advisors LLC acquired a new stake in shares of Moderna during the 2nd quarter worth about $3,140,000. Teachers Retirement System of The State of Kentucky lifted its stake in shares of Moderna by 4.3% during the 2nd quarter. Teachers Retirement System of The State of Kentucky now owns 283,909 shares of the company’s stock worth $33,714,000 after buying an additional 11,828 shares during the last quarter. Ariadne Wealth Management LP acquired a new stake in shares of Moderna during the 2nd quarter worth about $2,372,000. Granite Bay Wealth Management LLC bought a new position in Moderna during the second quarter worth about $524,000. Finally, Truist Financial Corp increased its position in Moderna by 7.3% during the second quarter. Truist Financial Corp now owns 18,657 shares of the company’s stock worth $2,216,000 after acquiring an additional 1,275 shares during the period. Institutional investors and hedge funds own 75.33% of the company’s stock.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.